cGAS STING Pathway Market - by Type, Molecule, Therapeutic Area, Route of Administration and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030
The cGAS STING pathway market is expected to reach USD 305 million in 2020 and anticipated to grow at a CAGR of 25% during the forecast period 2020-2030.
In recent years, considerable attention has been directed toward the cytosolic DNA sensing (cGAS-STING) pathway within the medical scientific community. This pathway presents a promising avenue for leveraging the immune system to address various clinical conditions, including oncological and autoimmune disorders, through pharmacological means. The manipulation of the STING pathway using modulators capable of either activating or suppressing it holds significant therapeutic potential. There are numerous such modulators developed, with more than 50 experimental interventions currently in progress for treating oncological, autoimmune, and inflammatory disorders. This growing interest is substantiated by the expanding body of scientific literature, with over 1,000 related articles on NCBI's PubMed since 2015. Additionally, substantial capital investments exceeding USD 2.6 billion from both public and private sectors have fueled product development in this area. Notably, several high-value technology licensing agreements have been made within the cGAS-STING pathway market since 2015. Consequently, there has been a surge in the establishment of companies dedicated to this field in the past 4-5 years, with major pharmaceutical players actively exploring multiple STING agonists/antagonists.
Moreover, recent molecular research into the pathogenesis of the novel SARS-CoV-2 virus suggests a potential association between COVID-19 and the STING pathway. This viral strain may induce a disorder related to STING, characterized by delayed over-secretion of IFN-?. Given the prominent expression of STING in human lung alveolar epithelial cells, endothelial cells, and spleen cells, which are crucial in COVID-19 pathogenesis, swift assessments of STING polymorphisms could assist in identifying individuals at high risk of severe infection. Furthermore, understanding the mechanisms behind the novel coronavirus-induced over-activation of the STING pathway may aid in the development of potential therapeutic candidates against COVID-19. Despite the absence of approved drugs or therapy products targeting the STING pathway currently available in the market, promising leads are expected to emerge over the next decade. Consequently, the market is forecasted to experience significant growth during this period.
Report Coverage
In recent years, considerable attention has been directed toward the cytosolic DNA sensing (cGAS-STING) pathway within the medical scientific community. This pathway presents a promising avenue for leveraging the immune system to address various clinical conditions, including oncological and autoimmune disorders, through pharmacological means. The manipulation of the STING pathway using modulators capable of either activating or suppressing it holds significant therapeutic potential. There are numerous such modulators developed, with more than 50 experimental interventions currently in progress for treating oncological, autoimmune, and inflammatory disorders. This growing interest is substantiated by the expanding body of scientific literature, with over 1,000 related articles on NCBI's PubMed since 2015. Additionally, substantial capital investments exceeding USD 2.6 billion from both public and private sectors have fueled product development in this area. Notably, several high-value technology licensing agreements have been made within the cGAS-STING pathway market since 2015. Consequently, there has been a surge in the establishment of companies dedicated to this field in the past 4-5 years, with major pharmaceutical players actively exploring multiple STING agonists/antagonists.
Moreover, recent molecular research into the pathogenesis of the novel SARS-CoV-2 virus suggests a potential association between COVID-19 and the STING pathway. This viral strain may induce a disorder related to STING, characterized by delayed over-secretion of IFN-?. Given the prominent expression of STING in human lung alveolar epithelial cells, endothelial cells, and spleen cells, which are crucial in COVID-19 pathogenesis, swift assessments of STING polymorphisms could assist in identifying individuals at high risk of severe infection. Furthermore, understanding the mechanisms behind the novel coronavirus-induced over-activation of the STING pathway may aid in the development of potential therapeutic candidates against COVID-19. Despite the absence of approved drugs or therapy products targeting the STING pathway currently available in the market, promising leads are expected to emerge over the next decade. Consequently, the market is forecasted to experience significant growth during this period.
Report Coverage
- The report conducts an analysis of the cGAS STING pathway market, focusing on STING modulator types, therapeutic areas, administration routes, molecule types, and key geographic regions.
- A comprehensive evaluation of factors impacting market growth, including drivers, restraints, opportunities, and challenges, is undertaken within the report.
- It assesses the potential benefits and barriers in the market landscape and provides insights into the competitive environment for leading market players.
- Revenue forecasts for market segments are provided across five distinct regions.
- The report offers an extensive examination of the current therapeutic market related to the STING pathway. This includes analyzing STING modulator classifications, molecule types, developmental phases, targeted therapeutic areas, treatment types, administration routes, and treatment lines.
- An in-depth analysis of the developer landscape is provided, encompassing details such as establishment year, company size, geographical locations, and an overview of ongoing clinical trials centered on the STING pathway.
- The report explores the technology platforms utilized for developing STING modulators, categorizing them based on modulator type, molecular composition, and analyzing technology developers considering establishment year, company size, and geographic distribution.
- Detailed profiles of key stakeholders involved in developing therapeutics targeting the STING pathway are provided based on the developmental phase of pipeline products. Each profile includes an overview of the company, financial information (if available), descriptions of leading drug candidates, recent advancements, and future outlook.
- Elaborate industry player profiles are tabulated based on antagonist pipeline products, detailing innovator company information, establishment year, headquarters location, employee count, key executives, recent developments, and descriptions of respective drug candidates.
- An analysis of grants awarded to research institutes involved in STING pathway projects between 2015 and Q1 2020 is conducted, considering parameters such as grant number, value, funding institutes, support periods, mechanisms, and recipient organizations.
- The report examines major pharmaceutical companies engaged in developing therapeutics targeting the STING pathway, covering aspects like portfolio diversity, molecule types, developmental phases, targeted therapeutic areas, therapy types, and administration routes.
- An analysis of start-ups and small players established within the last decade with fewer than 50 employees are conducted. Parameters such as portfolio diversity, molecule types, developmental phases, therapeutic areas, funding received, investor count, funding types, partnership activities, patent filings, grants received, and start-up health indexing are assessed.
- A comprehensive analysis of over 300 peer-reviewed scientific articles published between 2019 and Q1 2020 is conducted, focusing on research trends within the industry, highlighting publication types, study objectives, popular keywords, targeted pathways, therapeutic areas, and leading publishers.
- An analysis of partnerships established in the cGAS STING pathway market between 2015 and Q1 2020 is undertaken. This analysis covers various partnership types and examines patterns based on years, models, modulator types, therapeutic areas, technology platforms, and involved regions.
- An analysis of investments made across different developmental stages by companies engaged in the cGAS STING pathway market is performed. This includes evaluation of funding instances, invested amounts, funding types, modulator types, therapeutic areas, active players, investors, and geographical distribution.
- Aduro Biotech
- Bristol-Myers Squibb
- Eisai
- GlaxoSmithKline
- ImmuneSensor Therapeutics
- Merck
- Noxopharm
- Spring Bank Pharmaceuticals
- Synlogic
- STING Antagonist Developers
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Stimulator of Interferon Genes (STING) Pathway
3.2. STING Signaling
3.2.1. Relevance in Cancer
3.2.2. Relevance in Autoimmune Diseases
3.2.3. Relevance in Antimicrobial Host Defense
3.3. STING Pathway Modulators
3.3.1. STING Agonists
3.3.2. STING Antagonists
3.3.3. STING Activating Drug Delivery Systems
3.3.4. Indirect STING Activating Therapies
3.4. Key Variants of STING
3.5. Non-immunological Functions of the STING Pathway
3.6. Concluding Remarks
4. STING PATHWAY TARGETING THERAPEUTICS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. STING Pathway Targeting Therapeutics: Development Pipeline
4.2.1. Analysis by Type of STING Modulator
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Phase of Development
4.2.4. Analysis by Therapeutic Area
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Line of Treatment
4.3. STING Pathway Targeting Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geography
4.3.4. Most Active Players
4.4. STING Pathway Targeting Therapeutics: List of Clinical Trials
4.4.1. Analysis by Trial Recruitment Status
4.4.2. Analysis by Study Design
4.4.3. Analysis by Key Clinical Endpoints
5. STING PATHWAY TARGETING TECHNOLOGIES: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. STING Pathway Targeting Technologies: List of Technology Developers
5.2.1. Analysis by Type of Modulator
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Year of Establishment
5.2.4. Analysis by Company Size
5.2.5. Analysis by Geography
6. COMPANY PROFILES
6.1. Chapter Overview
6.2 STING Agonist Developers
6.2.1. Aduro Biotech
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Product Description: ADU-S100 (MIW815)
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Bristol-Myers Squibb
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Product Description: BMS-986301
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Eisai
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Product Description: E7766
6.2.3.4. Recent Developments and Future Outlook
6.2.4 GlaxoSmithKline
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Product Description: GSK3745417
6.2.4.4. Recent Developments and Future Outlook
6.2.5. ImmuneSensor Therapeutics
6.2.5.1. Company Overview
6.2.5.2. Product Description: IMSA101
6.2.6. Merck
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Product Description: MK-1454 and MK-2118
6.2.6.4. Recent Developments and Future Outlook
6.2.7. Noxopharm
6.2.7.1. Company Overview
6.2.7.2. Product Description: NOX66
6.2.7.3. Recent Developments and Future Outlook
6.2.8. Spring Bank Pharmaceuticals
6.2.8.1. Company Overview
6.2.8.2. Financial Information
6.2.8.3. Product Description: SB 11285
6.2.8.4. Recent Developments and Future Outlook
6.2.9. Synlogic
6.2.9.1. Company Overview
6.2.9.2. Financial Information
6.2.9.3. Product Description: SYNB1891
6.2.9.4. Recent Developments and Future Outlook
6.3. STING Antagonist Developers
6.3.1 Avammune Therapeutics
6.3.2. Curadev
6.3.3 ImmuneSensor Therapeutics
6.3.4. Nimbus Therapeutics
6.3.5. Sirenas
6.3.6. Spring Bank Pharmaceuticals
6.3.7. STINGINN
6.3.8. STipe Therapeutics
7. ACADEMIC GRANT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. STING Pathway Targeting Therapeutics: List of Academic Grants
7.3.1. Analysis by Number of Grants
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Funding Institute
7.3.4. Analysis by Support Period
7.3.5. Analysis by Funding Mechanism
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Grant Activity Code
7.3.8. Analysis by Funding Institutes
7.3.9. Analysis by Type of Recipient Organization
7.3.10 Regional Distribution of Grant Recipients
7.3.11 Most Popular Recipient Organizations: Analysis by Number of Grants and Amount Invested
7.3.12. Prominent Project Leaders: Analysis by Number of Grants
7.3.13 Analysis by Support Year and Amount Awarded
7.3.14. Analysis by Study Section
7.4. Grant Attractiveness Analysis
8. STING RELATED INITIATIVES OF BIG PHARMACEUTICALS PLAYERS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Initiatives Undertaken by Big Pharma Players
8.3.1. Analysis by Portfolio Diversity
8.3.2. Analysis by Type of Molecule
8.3.3. Analysis by Phase of Development
8.3.4. Analysis by Therapeutic Area
8.3.5. Analysis by Type of Therapy
8.3.6. Analysis by Route of Administration
8.4. Benchmarking Big Pharma Players
8.4.1 Spider Web Analysis: AbbVie
8.4.2. Spider Web Analysis: Bayer
8.4.3. Spider Web Analysis: Bristol-Myers Squibb
8.4.4. Spider Web Analysis: Celgene
8.4.5. Spider Web Analysis: Eisai
8.4.6. Spider Web Analysis: Eli Lily
8.4.7. Spider Web Analysis: Genentech
8.4.8. Spider Web Analysis: GlaxoSmithKline
8.4.9. Spider Web Analysis: Merck
8.4.10. Spider Web Analysis: Novartis
8.4.11. Spider Web Analysis: Novo Nordisk
8.4.12. Spider Web Analysis: Pfizer
8.4.13. Spider Web Analysis: Roche
8.4.14. Spider Web Analysis: Takeda Pharmaceuticals
9. START-UP HEALTH INDEXING
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Benchmarking of Start-ups
9.3.1. Analysis by Portfolio Diversity
9.3.2. Analysis by Type of Molecule
9.3.3. Analysis by Phase of Development
9.3.4 Analysis by Therapeutic Area
9.3.5. Analysis by Funding Amount
9.3.6. Analysis by Number of Investors
9.3.7. Analysis by Type of Funding
9.3.8. Analysis by Partnership Activity
9.3.9. Analysis by Other Parameters
9.3.10. Analysis by Location of Headquarters
9.3.11. Start-up Health Indexing: Roots Analysis Perspective
10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. STING Pathway Targeting Therapeutics: Recent Publications
10.3.1. Analysis by Type of Publication
10.3.2. Analysis by Type of Publication and Year
10.3.3. Analysis by Study Objective
10.3.4. Analysis by Popular Keywords
10.3.5. Analysis by Type of STING Modulator
10.3.6. Analysis by Target Pathway
10.3.7. Analysis by Therapeutic Area
10.3.8. Analysis by Type of STING Modulator and Therapeutic Area
10.3.9 Analysis by Type of Publisher
10.3.10. Leading Players: Analysis by Number of Publications
10.3.11. Leading Players: Geographical Analysis by Number of Publications
10.3.12. Analysis by First Author Organization
10.3.13. Key Journals: Analysis by Number of Publications
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. STING Pathway Targeting Therapeutics: Recent Partnerships
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3 Analysis by Type of STING Modulator
11.3.4. Analysis by Therapeutic Area
11.3.5. Analysis by Technology Platform
11.3.6. Most Active Players: Analysis by Number of Partnerships
11.3.7. Geographical Analysis
11.3.7.1 Most Active Players: Analysis by Number of partnerships
11.3.7.2. Intercontinental and Intracontinental Agreements
12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. STING Pathway Targeting Therapeutics: Recent Funding Instances
12.3.1. Analysis by Number of Funding Instances
12.3.2. Analysis by Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Type of STING Modulator
12.3.6. Analysis by Therapeutic Area
12.3.6 Analysis by Amount Invested and Type of STING Technology Platform
12.3.7. Most Active Players: Analysis by Number of Funding Instances
12.3.8. Most Active Investors: Analysis by Number of Funding Instances
12.3.9. Geographical Analysis by Amount Invested
12.4. Concluding Remarks
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global STING Pathway Targeting Technologies Market, 2020-2030
13.3.1. STING Pathway Targeting Technologies Market by Upfront Payments, 2020-2030
13.3.2. STING Pathway Targeting Technologies Market by Milestone Payments, 2020-2030
13.3.3. STING Pathway Targeting Technologies Market: Distribution by Type of STING Modulator
13.3.3.1. STING Pathway Targeting Technologies Market for Agonist, 2020-2030
13.3.3.2. STING Pathway Targeting Technologies Market for Antagonist, 2020-2030
13.3.4. STING Pathway Targeting Technologies Market: Distribution by Therapeutic Area
13.3.4.1. STING Pathway Targeting Technologies Market for Oncological Disorders, 2020-2030
13.3.4.2. STING Pathway Targeting Technologies Market for Inflammatory Disorders, 2020-2030
13.3.4.3. STING Pathway Targeting Technologies Market for Infectious Diseases, 2020-2030
13.3.4.4. STING Pathway Targeting Technologies Market for Other Therapeutic Areas, 2020-2030
13.3.5. STING Pathway Targeting Technologies Market: Distribution by Route of Administration
13.3.5.1. STING Pathway Targeting Technologies Market for Intratumoral Route, 2020-2030
13.3.5.2. STING Pathway Targeting Technologies Market for Intravenous Route, 2020-2030
13.3.5.3. STING Pathway Targeting Technologies Market for Oral Route, 2020-2030
13.3.5.4. STING Pathway Targeting Technologies Market for Subcutaneous Route, 2020-2030
13.3.5.5. STING Pathway Targeting Technologies Market for Other Routes, 2020-2030
13.3.6. STING Pathway Targeting Technologies Market: Distribution by Type of Molecule
13.3.6.1. STING Pathway Targeting Technologies Market for Non-Nucleotide, 2020-2030
13.3.6.2. STING Pathway Targeting Technologies Market for Cyclic Dinucleotide, 2020-2030
13.3.6.3. STING Pathway Targeting Technologies Market for Live Biotherapeutics, 2020-2030
13.3.6.4. STING Pathway Targeting Technologies Market for Oncolytic Viruses, 2020-2030
13.3.6.5. STING Pathway Targeting Technologies Market for Synthetic Peptides, 2020-2030
13.3.6.6. STING Pathway Targeting Technologies Market for Other Molecules, 2020-2030
13.3.7. STING Pathway Targeting Technologies Market: Distribution by Geography
13.3.7.1. STING Pathway Targeting Technologies Market in North America, 2020-2030
13.3.7.2. STING Pathway Targeting Technologies Market in Europe, 2020-2030
13.3.7.3. STING Pathway Targeting Technologies Market in Asia-Pacific, 2020-2030
14. EXECUTIVE INSIGHTS
15. CONCLUDING REMARKS
15.1. Chapter Overview
15.2. Key Takeaways
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Stimulator of Interferon Genes (STING) Pathway
3.2. STING Signaling
3.2.1. Relevance in Cancer
3.2.2. Relevance in Autoimmune Diseases
3.2.3. Relevance in Antimicrobial Host Defense
3.3. STING Pathway Modulators
3.3.1. STING Agonists
3.3.2. STING Antagonists
3.3.3. STING Activating Drug Delivery Systems
3.3.4. Indirect STING Activating Therapies
3.4. Key Variants of STING
3.5. Non-immunological Functions of the STING Pathway
3.6. Concluding Remarks
4. STING PATHWAY TARGETING THERAPEUTICS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. STING Pathway Targeting Therapeutics: Development Pipeline
4.2.1. Analysis by Type of STING Modulator
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Phase of Development
4.2.4. Analysis by Therapeutic Area
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Line of Treatment
4.3. STING Pathway Targeting Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geography
4.3.4. Most Active Players
4.4. STING Pathway Targeting Therapeutics: List of Clinical Trials
4.4.1. Analysis by Trial Recruitment Status
4.4.2. Analysis by Study Design
4.4.3. Analysis by Key Clinical Endpoints
5. STING PATHWAY TARGETING TECHNOLOGIES: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. STING Pathway Targeting Technologies: List of Technology Developers
5.2.1. Analysis by Type of Modulator
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Year of Establishment
5.2.4. Analysis by Company Size
5.2.5. Analysis by Geography
6. COMPANY PROFILES
6.1. Chapter Overview
6.2 STING Agonist Developers
6.2.1. Aduro Biotech
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Product Description: ADU-S100 (MIW815)
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Bristol-Myers Squibb
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Product Description: BMS-986301
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Eisai
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Product Description: E7766
6.2.3.4. Recent Developments and Future Outlook
6.2.4 GlaxoSmithKline
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Product Description: GSK3745417
6.2.4.4. Recent Developments and Future Outlook
6.2.5. ImmuneSensor Therapeutics
6.2.5.1. Company Overview
6.2.5.2. Product Description: IMSA101
6.2.6. Merck
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Product Description: MK-1454 and MK-2118
6.2.6.4. Recent Developments and Future Outlook
6.2.7. Noxopharm
6.2.7.1. Company Overview
6.2.7.2. Product Description: NOX66
6.2.7.3. Recent Developments and Future Outlook
6.2.8. Spring Bank Pharmaceuticals
6.2.8.1. Company Overview
6.2.8.2. Financial Information
6.2.8.3. Product Description: SB 11285
6.2.8.4. Recent Developments and Future Outlook
6.2.9. Synlogic
6.2.9.1. Company Overview
6.2.9.2. Financial Information
6.2.9.3. Product Description: SYNB1891
6.2.9.4. Recent Developments and Future Outlook
6.3. STING Antagonist Developers
6.3.1 Avammune Therapeutics
6.3.2. Curadev
6.3.3 ImmuneSensor Therapeutics
6.3.4. Nimbus Therapeutics
6.3.5. Sirenas
6.3.6. Spring Bank Pharmaceuticals
6.3.7. STINGINN
6.3.8. STipe Therapeutics
7. ACADEMIC GRANT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. STING Pathway Targeting Therapeutics: List of Academic Grants
7.3.1. Analysis by Number of Grants
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Funding Institute
7.3.4. Analysis by Support Period
7.3.5. Analysis by Funding Mechanism
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Grant Activity Code
7.3.8. Analysis by Funding Institutes
7.3.9. Analysis by Type of Recipient Organization
7.3.10 Regional Distribution of Grant Recipients
7.3.11 Most Popular Recipient Organizations: Analysis by Number of Grants and Amount Invested
7.3.12. Prominent Project Leaders: Analysis by Number of Grants
7.3.13 Analysis by Support Year and Amount Awarded
7.3.14. Analysis by Study Section
7.4. Grant Attractiveness Analysis
8. STING RELATED INITIATIVES OF BIG PHARMACEUTICALS PLAYERS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Initiatives Undertaken by Big Pharma Players
8.3.1. Analysis by Portfolio Diversity
8.3.2. Analysis by Type of Molecule
8.3.3. Analysis by Phase of Development
8.3.4. Analysis by Therapeutic Area
8.3.5. Analysis by Type of Therapy
8.3.6. Analysis by Route of Administration
8.4. Benchmarking Big Pharma Players
8.4.1 Spider Web Analysis: AbbVie
8.4.2. Spider Web Analysis: Bayer
8.4.3. Spider Web Analysis: Bristol-Myers Squibb
8.4.4. Spider Web Analysis: Celgene
8.4.5. Spider Web Analysis: Eisai
8.4.6. Spider Web Analysis: Eli Lily
8.4.7. Spider Web Analysis: Genentech
8.4.8. Spider Web Analysis: GlaxoSmithKline
8.4.9. Spider Web Analysis: Merck
8.4.10. Spider Web Analysis: Novartis
8.4.11. Spider Web Analysis: Novo Nordisk
8.4.12. Spider Web Analysis: Pfizer
8.4.13. Spider Web Analysis: Roche
8.4.14. Spider Web Analysis: Takeda Pharmaceuticals
9. START-UP HEALTH INDEXING
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Benchmarking of Start-ups
9.3.1. Analysis by Portfolio Diversity
9.3.2. Analysis by Type of Molecule
9.3.3. Analysis by Phase of Development
9.3.4 Analysis by Therapeutic Area
9.3.5. Analysis by Funding Amount
9.3.6. Analysis by Number of Investors
9.3.7. Analysis by Type of Funding
9.3.8. Analysis by Partnership Activity
9.3.9. Analysis by Other Parameters
9.3.10. Analysis by Location of Headquarters
9.3.11. Start-up Health Indexing: Roots Analysis Perspective
10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. STING Pathway Targeting Therapeutics: Recent Publications
10.3.1. Analysis by Type of Publication
10.3.2. Analysis by Type of Publication and Year
10.3.3. Analysis by Study Objective
10.3.4. Analysis by Popular Keywords
10.3.5. Analysis by Type of STING Modulator
10.3.6. Analysis by Target Pathway
10.3.7. Analysis by Therapeutic Area
10.3.8. Analysis by Type of STING Modulator and Therapeutic Area
10.3.9 Analysis by Type of Publisher
10.3.10. Leading Players: Analysis by Number of Publications
10.3.11. Leading Players: Geographical Analysis by Number of Publications
10.3.12. Analysis by First Author Organization
10.3.13. Key Journals: Analysis by Number of Publications
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. STING Pathway Targeting Therapeutics: Recent Partnerships
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3 Analysis by Type of STING Modulator
11.3.4. Analysis by Therapeutic Area
11.3.5. Analysis by Technology Platform
11.3.6. Most Active Players: Analysis by Number of Partnerships
11.3.7. Geographical Analysis
11.3.7.1 Most Active Players: Analysis by Number of partnerships
11.3.7.2. Intercontinental and Intracontinental Agreements
12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. STING Pathway Targeting Therapeutics: Recent Funding Instances
12.3.1. Analysis by Number of Funding Instances
12.3.2. Analysis by Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Type of STING Modulator
12.3.6. Analysis by Therapeutic Area
12.3.6 Analysis by Amount Invested and Type of STING Technology Platform
12.3.7. Most Active Players: Analysis by Number of Funding Instances
12.3.8. Most Active Investors: Analysis by Number of Funding Instances
12.3.9. Geographical Analysis by Amount Invested
12.4. Concluding Remarks
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global STING Pathway Targeting Technologies Market, 2020-2030
13.3.1. STING Pathway Targeting Technologies Market by Upfront Payments, 2020-2030
13.3.2. STING Pathway Targeting Technologies Market by Milestone Payments, 2020-2030
13.3.3. STING Pathway Targeting Technologies Market: Distribution by Type of STING Modulator
13.3.3.1. STING Pathway Targeting Technologies Market for Agonist, 2020-2030
13.3.3.2. STING Pathway Targeting Technologies Market for Antagonist, 2020-2030
13.3.4. STING Pathway Targeting Technologies Market: Distribution by Therapeutic Area
13.3.4.1. STING Pathway Targeting Technologies Market for Oncological Disorders, 2020-2030
13.3.4.2. STING Pathway Targeting Technologies Market for Inflammatory Disorders, 2020-2030
13.3.4.3. STING Pathway Targeting Technologies Market for Infectious Diseases, 2020-2030
13.3.4.4. STING Pathway Targeting Technologies Market for Other Therapeutic Areas, 2020-2030
13.3.5. STING Pathway Targeting Technologies Market: Distribution by Route of Administration
13.3.5.1. STING Pathway Targeting Technologies Market for Intratumoral Route, 2020-2030
13.3.5.2. STING Pathway Targeting Technologies Market for Intravenous Route, 2020-2030
13.3.5.3. STING Pathway Targeting Technologies Market for Oral Route, 2020-2030
13.3.5.4. STING Pathway Targeting Technologies Market for Subcutaneous Route, 2020-2030
13.3.5.5. STING Pathway Targeting Technologies Market for Other Routes, 2020-2030
13.3.6. STING Pathway Targeting Technologies Market: Distribution by Type of Molecule
13.3.6.1. STING Pathway Targeting Technologies Market for Non-Nucleotide, 2020-2030
13.3.6.2. STING Pathway Targeting Technologies Market for Cyclic Dinucleotide, 2020-2030
13.3.6.3. STING Pathway Targeting Technologies Market for Live Biotherapeutics, 2020-2030
13.3.6.4. STING Pathway Targeting Technologies Market for Oncolytic Viruses, 2020-2030
13.3.6.5. STING Pathway Targeting Technologies Market for Synthetic Peptides, 2020-2030
13.3.6.6. STING Pathway Targeting Technologies Market for Other Molecules, 2020-2030
13.3.7. STING Pathway Targeting Technologies Market: Distribution by Geography
13.3.7.1. STING Pathway Targeting Technologies Market in North America, 2020-2030
13.3.7.2. STING Pathway Targeting Technologies Market in Europe, 2020-2030
13.3.7.3. STING Pathway Targeting Technologies Market in Asia-Pacific, 2020-2030
14. EXECUTIVE INSIGHTS
15. CONCLUDING REMARKS
15.1. Chapter Overview
15.2. Key Takeaways
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
